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Abstract: Gonorrhea is a set of clinical conditions resulting from infection with the sexually-
acquired bacterial pathogen Neisseria gonorrhoeae. Acquisition may involve multiple mucosal 
sites in the lower female genital tract, including the urethra, cervix, Bartholin’s and Skene’s 
glands, as well as the anorectal canal, pharynx, and conjunctivae. It may spread to the upper 
genital tract, uterine tubes, abdominal cavity, and other systemic sites. Gonorrhea is the sec-
ond most commonly reported sexually-transmitted infection in the US and rates are higher 
among women than men. Women and infants are affected disproportionately by gonorrhea, 
because early infection may be asymptomatic and also because extension of infection is often 
associated with serious sequelae. Screening is critical for infection identification and the 
prevention or limitation of upper genital tract spread, and horizontal and vertical transmis-
sion. Routine genital screening is recommended annually for all sexually active women at 
risk for infection, including women aged , 25 years and older women with one or more of 
the following risks: a previous gonorrhea infection, the presence of other sexually transmit-
ted diseases, new or multiple sex partners, inconsistent condom use, commercial sex work, 
drug use, or human immunodeficiency virus infection with sexual activity or pregnancy. 
Pharyngeal gonococcal infections are common in adolescents, and direct culture screen-
ing is necessary to identify affected individuals. Nucleic acid amplification tests (NAATs) 
are considered the standard for screening and diagnosis. Although urine NAAT testing is 
most commonly used, there is growing support for vaginal swabs collected by providers or 
patients themselves. Resistance to all antibiotics currently recommended for the treatment 
of gonorrhea has been documented and complicates therapeutic strategies. The Centers for 
Disease Control and Prevention recommend treatment of gonorrhea with a single class of 
drugs, ie, the cephalosporins.
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Introduction
Gonorrhea refers to a set of clinical conditions involving infection with the sexually 
acquired bacterial pathogen, Neisseria gonorrhoeae, identified microbiologically 
by its Gram-negative intracellular diplococci. N. gonorrhoeae may be acquired 
at multiple mucosal sites in the lower genital tract, including the urethra, cervix, 
Bartholin’s and Skene’s glands, as well as through the anorectal canal, pharynx, and 
conjunctivae. It may spread to the upper genital tract, uterine tubes, and abdomi-
nal cavity, as well as other systemic sites. With references to this condition dating 
back over 2000 years, gonorrhea is an old disease, with humans serving as the sole 
natural host.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Epidemiologic features
Prevalence
Gonorrhea is a common infection, with recent Centers for 
Disease Control and Prevention (CDC) figures estimating 
more than 700,000 new cases in the US each year, only half 
of which are reported.1 In 2009, there were 301,174 cases of 
gonorrhea reported in the US, a rate of 99.1 cases per 100,000 
people, a 10.5% decrease from the previous year. Gonorrhea 
follows chlamydial infections as the second most commonly 
reported sexually transmitted infection (STI) in the US.1 
As a treatable STI, gonorrhea rates respond to public health 
interventions aimed at aggressive case   finding and treatment, 
and between 1975 and 1997, rates fell 74% in response 
to a national gonorrhea control program.   Following the 
conclusion of that program, gonorrhea rates have remained 
relatively stable.
Overall rates and comparisons between subpopulations 
must be understood within the context that reported case 
results are greatly influenced by changes in public awareness, 
health care access, screening practices, resistance patterns, 
reporting practices, outbreaks of other STIs, and budgetary 
limitations that hamper the abilities of public health officials 
to monitor disease patterns accurately.1,2 In particular, rates of 
asymptomatic infections are subject to dramatic shifts based 
on alterations in screening behaviors.3–6
Reported rates of gonorrhea and other STIs are   commonly 
held to represent the tip of the iceberg of true infection preva-
lence, in large part because roughly half of all   gonococcal 
infections in women are asymptomatic.7 Some have 
  cautioned that actual prevalence is likely to be roughly twice 
the reported rate.8 Problems that evolve from that paradigm 
are that many infected individuals harbor untreated infec-
tion for protracted periods of time, greatly increasing the 
potential both for transmission of infection to sex partners 
and development of complications due to more profound 
extension of the infection.1
Given the biased and incomplete nature of passive case 
reporting, active surveillance efforts are used to assess 
disease burden in selected higher risk populations. In 2009, 
the median state-specific gonorrhea test positivity among 
women aged 15–24 years in a subset of states, the District 
of Columbia, Puerto Rico, and the Virgin Islands, was ascer-
tained through screening efforts in various settings: family 
planning clinics 1.0% (range 0.0%–3.4%); prenatal clinics 
1.2% (range 0.0%–5.5%); women entering the National Job 
Training Program 1.6% (0.0%–5%); and women entering 
juvenile corrections facilities 2.9% (0.0%–13.4%).1
Geographic distribution
Prevalence in the US varies by geography and demograph-
ics, with the highest risk profile in adolescent black women 
residing in urban locales in the South. The South has tradi-
tionally had the highest rates in the US, followed closely 
by the Midwest. State-reported gonorrhea rates fell in 84% 
of states between 2008 and 2009.1 In 2009, gonorrhea rates 
per 100,000 population by state ranged from 7.2 in Utah to 
246.4 in Mississippi. The majority of people with   gonorrhea 
reside in urban locations, with 60% of gonorrhea cases 
reported by the 50 most populous metropolitan areas that 
report to the CDC in 2009.
Gender
Traditionally, men were more likely to have gonorrhea, but 
rates equilibrated by 1996 and have remained similar since 
then.1 In 2009, the gonorrhea rate among women was higher 
than the rate among men, and the most common reporting 
source for women was private physicians/health maintenance 
organizations (30.9%), followed by STI clinics (16.7%), 
  family planning clinics (9.1%), other health department 
clinics (8.1%), and emergency rooms (5.8%).
Race and age
Gonorrhea rates are highest among blacks, and in 2009 the 
rate in black women was 17 times greater than the rate among 
white women.1 Adolescents and young adults bear the greatest 
burden of infection. Among females in 2009, black women 
aged 15–19 years and 20–24 years had the highest rates of 
gonorrhea (2614 and 2549 per 100,000, respectively).
education
Education has been inversely correlated to behavioral 
risk-taking associated with the acquisition of STIs in 
adolescents.9–13 A recent study of self-reported STIs, includ-
ing gonorrhea, chlamydia, and trichomoniasis, among young 
adult women confirmed that education is associated with 
decreased engagement in sexual risk behaviors and lower 
rates of STI diagnosis, but that those associations varied 
across racial strata, with college-educated black women 
reporting higher rates of STI compared with white women 
who had not completed high school.8
Clinical manifestations
Women and infants are affected disproportionately by gon-
orrhea, because early infection may be asymptomatic or 
subclinical and also because extension of infection is often International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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associated with serious sequelae. The simplest gonococcal 
infections in women involve mucosal surfaces of the 
  endocervix, urethra, anus, or pharynx. Most such infections 
are either silent or generate only mild symptoms, including 
discharge and mild irritation, that may or may not be appre-
ciated until the infection spreads to the upper genital tract. 
Pharyngeal infections are nearly always asymptomatic. When 
an etiologic organism is isolated in the presence of cervicitis, 
it is typically Chlamydia trachomatis or N. gonorrhoeae. 
Because cervicitis might be a sign of upper genital tract 
infection, women who seek medical treatment for a new epi-
sode of cervicitis should be assessed for pelvic inflammatory 
  disease. An estimated 10%–20% of women with gonorrrhea 
or chlamydia may develop pelvic inflammatory disease if their 
infection is not identified and they do not receive adequate 
treatment.14 Among women with pelvic inflammatory disease, 
uterine tubal scarring can cause involuntary infertility in 20% 
of women, ectopic pregnancy in 9%, and chronic pelvic pain 
in 18%.15 Some cases of pelvic inflammatory disease have a 
severe presentation with abdominal pain and fever, and may 
result in tubo-ovarian abscesses and systemic infection. As 
with uncomplicated gonococcal infection, many women 
with pelvic inflammatory disease are asymptomatic or have 
subtle signs and symptoms of ongoing damage to uterine 
tubes, resulting in treatment delays in approximately 85% 
of women with pelvic inflammatory disease and enhancing 
the chance for long-term sequelae.15,16
Gonorrhea can become disseminated, with bacteremia 
leading on occasion to chronic joint infections and sepsis. 
  Disseminated gonorrhea frequently results in petechial or pus-
tular acral skin lesions, asymmetrical arthralgia,   tenosynovitis, 
or septic arthritis. The infection is complicated occasionally 
by perihepatitis and rarely by endocarditis or meningitis.
Finally, gonorrhea is highly transmissible, both to sexual 
contacts and at birth. Infections in the neonate include con-
junctivitis, blindness, sepsis, and joint infections.
Screening
Because gonorrhea is often asymptomatic in women, screen-
ing is critical for the identification of infection and the preven-
tion or limitation of upper genital tract spread, and horizontal 
and vertical transmission. Data from a randomized controlled 
trial of chlamydia screening in a managed care setting sug-
gest that such screening programs can reduce the incidence 
of pelvic inflammatory disease by as much as 60%.17
Because the prevalence of gonorrhea varies widely 
among communities and populations, targeted rather than 
widespread screening is recommended by the US Preventive 
Services Task Force and the CDC. Routine genital screening 
for N. gonorrhoeae is recommended annually for all sexu-
ally active women at risk for infection, including women 
aged , 25 years and older women with one or more of the 
following risks: a previous gonorrhea infection, the presence 
of other STIs, new or multiple sex partners, inconsistent con-
dom use, commercial sex work, drug use, or human immuno-
deficiency virus infection with sexual activity.18 Pharyngeal 
gonococcal infections are common in some segments of the 
population, especially adolescents, and pharyngeal culture 
screening is responsible for identification of up to one-quarter 
of infected adolescent women who would likely be missed 
with traditional genital tract screening.19–23
All pregnant women at risk for gonorrhea or living in an 
area in which the prevalence of N. gonorrhoeae is high should 
be screened at the first prenatal visit for N. gonorrhoeae.18 
Pregnant women who test positive should be retested within 
approximately 3–6 months, and those who remain at high 
risk for gonococcal infection, including adolescents, should 
be retested also during the third trimester.24
Specific testing for N. gonorrhoeae is recommended 
because of the subtle and nonspecific nature of presentation 
in most women as well as the availability of highly sensitive 
and specific testing modalities. Although there are three 
ways to diagnose gonorrhea, ie, traditional culture, nucleic 
acid hybridization, and nucleic acid amplification tests 
(NAATs), NAATs are considered the standard for screen-
ing and diagnostic purposes currently. Culture requires 
collection of actual cells from infected mucosal surfaces, 
and is the only methodology approved for detection of 
N. gonorrhoeae from both genital (endocervical, urethral) 
and nongenital (anorectal, pharyngeal, and conjunctival) 
mucosal surfaces. Cultures can provide antimicrobial sus-
ceptibility results, and should be the test of choice in cases 
of suspected or documented treatment failure. Nucleic acid 
hybridization tests detect gonococcal DNA and some brands 
also test for chlamydial DNA; they are recommended for 
use on specimens collected from genital tract surfaces, 
including genital tract, vagina, and urine. The principal 
types of NAATs, ie, transcription-mediated amplifica-
tion, polymerase chain reactions, and strand displacement 
amplification, detect and copy gonococcal DNA to enhance 
detection. NAATs are approved by the US Food and Drug 
Administration for use with urine, urethral, and endocer-
vical samples, and some are cleared for use on vaginal 
swabs, but none are approved for use in specimens from the International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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rectum, oropharynx, or conjunctivae due to concerns that 
specificity could be compromised by   cross-reaction with 
  nongonococcal Neisseria species. NAATs have demon-
strated improved sensitivity and specificity compared with 
culture for the detection of N. gonorrhoeae at rectal and 
oropharyngeal sites among men.21,22,25,26 Numerous public 
and private laboratories have established performance 
specifications for using NAAT with vaginal, rectal, and 
pharyngeal swab specimens, thereby allowing results to be 
used for clinical management. Under these circumstances, 
NAATs are preferred for rectal, oropharyngeal, and conjunc-
tival specimens. Liquid-based cervical cytology specimens 
appear to hold promise for NAAT testing, although test 
sensitivity using these specimens might be lower than those 
resulting from the use of cervical swab specimens.27
Although the standard female genital screening tool at 
most public health clinics is urine NAAT testing, there is 
growing support for vaginal swabs collected by providers 
and patients in clinical and nonclinical settings. Vaginal swab 
specimens perform at least as well as with other approved 
specimens using NAATs, and women find this screening 
strategy highly acceptable.31,32 In a study of women using 
long-acting contraception who remain at risk of STI acqui-
sition, those randomized to self-collected vaginal swabs 
were more likely to complete screening than the women 
in the traditional clinical screening group.33 Another study 
showed that women recruited by the Internet demonstrated 
higher positivity of chlamydia than those attending a family 
planning clinic, providing an important at-risk market for 
self-collected vaginal swabs.34 Finally, as a practical mat-
ter, swabs reduce biological waste associated with urine 
testing.
In symptomatic women, the finding of .10 white blood 
cells per high powered field in vaginal fluid in the absence 
of trichomoniasis, may reflect endocervical inflammation 
caused by C. trachomatis or N. gonorrhoeae,28,29 and should 
increase motivation for empiric treatment.
Due to high prevalence of gonorrhea in juvenile detention 
and jail facilities, the CDC recommends universal screening 
at intake of adolescent and adult women up to 35 years of age 
or on the basis of local institutional prevalence data.1
Routine testing of inmates has the potential to diagnose 
a large portion of STIs in the community. When the Cook 
County Jail in Chicago stopped offering routine chlamydia 
and gonorrhea testing to all male inmates, approximately 
90% fewer detainees were diagnosed with either disease 
and citywide diagnosis in males and females decreased 
by 9.3% for chlamydia and 12.9% for   gonorrhea.5 Failure 
to perform universal screening in high-risk populations 
represents a missed opportunity to uncover substantial 
numbers of infections. When New York City began routine 
testing for chlamydia and gonorrhea among incarcerated 
men less than 35 years of age, the citywide diagnosis 
of chlamydia and gonorrhea increased by 59% and 4%, 
respectively.6 Kahn examined the link between incar-
ceration and sexually transmitted infections from a social 
network perspective in Brooklyn, NY (n = 343) and found 
that acquisition of an STI was highly associated with a 
history of incarceration.30
Persons with gonorrhea should be tested for other STIs. 
Outside of the neonatal period, evidence of gonococcal 
infection at any site is considered virtually 100% indicative 
of sexual contact.35
Management
Antimicrobial-resistant N. gonorrhoeae
Gonorrhea treatment is complicated by the ability of 
N.   gonorrhoeae to develop resistance to antimicrobial 
therapies.36 In 1986, the CDC developed a national surveil-
lance program called the Gonococcal Isolate Surveillance 
Project to monitor gonococcal isolate resistance patterns in 
the US among selected STI clinics in approximately 25–30 
Gonococcal Isolate Surveillance Project sentinel sites and 
4–5 regional laboratories.
Penicillin was the original treatment choice for gono-
coccal infections until the discovery in 1976 of resistance 
mediated by plasmid production of β-lactamase.37 Rates 
of penicillinase-producing N. gonorrhoeae have risen 
steadily since then, and chromosomal-mediated resistant 
N. gonorrhoeae has emerged to tetracycline, cephosporins, 
spectinomycin, and aminoglycosides.38 Newer findings 
include plasmid-mediated tetracycline resistance resulting 
from acquisition of a tet-M gene38–40 and fluoroquinolone 
resistance.1,41
Treatment with quinolones used to be the mainstay of 
N. gonorrhoeae treatment in the US, but resistant strains 
spread throughout the US and the world,42 leading to removal 
of that class of drugs from recommendations for the treatment 
of gonorrhea and pelvic inflammatory disease in April 2007.43 
Provider compliance has been excellent, with the proportion 
of Gonococcal Isolate Surveillance Project patients treated 
with fluoroquinolones (ciprofloxacin, ofloxacin, or levofloxa-
cin) at 0.5% and the proportion treated with cephalosporins 
at 96.2% in 2009. By 2009, 23.5% of isolates collected from 
Gonococcal Isolate Surveillance Project sites were resistant 
to penicillin, tetracycline, or ciprofloxacin.1International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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Decreased susceptibility has been documented to 
  azithromycin in US isolates of N. gonorrhoeae,1 and 
resistant strains have been documented internationally.44–47 
Most of the treatment failures resulting from use of 
oral   cephalosporins have been reported from Asian and 
European countries,48–51 although one possible case was 
reported in Hawaii in 2001.52 To ensure appropriate antibi-
otic therapy, clinicians should ask patients testing positive 
for gonorrhea about recent travel to and sexual activity in 
these countries. Two cases of suspected treatment failure 
with ceftriaxone have been reported.53 Decreased suscep-
tibility of N. gonorrhoeae to cephalosporins and other 
antimicrobials is expected to continue to spread; therefore, 
state and local surveillance for antimicrobial resistance 
is crucial for   guiding local therapy   recommendations.36 
The CDC website (http://www.cdc.gov/std/gisp) and 
state health departments can provide the most current 
information.
Antimicrobial regimens
While gonorrhea is a bacterial infection that responds to a 
number of antibiotics, resistance to all   antibiotic treatments 
currently recommended for the   treatment of gonorrhea has 
been documented and complicate therapeutic strategies. 
The CDC released new STI treatment guidelines in 2010, 
with evidence-based antibiotic regimens designed to treat 
gonorrhea by anatomic site of infection (Table 1).35 The 
recommended treatment of gonorrhea has been limited to a 
single class of drugs, the cephalosporins. The regimens listed 
in Table 1 are recommended for treatment of uncomplicated 
lower genital tract and anorectal gonococcal infection in 
women. Treatment should be administered or dispensed at 
the time of diagnosis to maximize patient adherence. Patients 
should be instructed to abstain from sexual intercourse until 
therapy is completed and until they and their sex partners no 
longer have symptoms.
Uncomplicated gonococcal  
infections
Ceftriaxone has been shown to cure 99.2% of uncompli-
cated urogenital and anorectal and 98.9% of pharyngeal 
infections in published clinical trials.49,50 While a dose of 
125 mg was recommended until recently for lower genital 
and anorectal infection, a doubling of the dose is recom-
mended to reduce development of resistance and to cover 
unrecognized oropharyngeal infection. Other injectable 
cephalosporins recommended for gonococcal treatment 
include ceftizoxime, cefoxitin, and cefotaxime. None of 
these offers any advantage over ceftriaxone for urogenital 
infection, and efficacy for pharyngeal infection is less 
certain.54,55 The only   recommended oral choice for gonor-
rhea is cefixime, which has a lower cure rate at 97.5% for 
uncomplicated urogenital and anorectal and 92.3% of pha-
ryngeal gonococcal infections. Published sources estimate 
that approximately 50 patients are thought to have failed oral 
cephalosporin treatment.49,56–59
The 2 g dose of azithromycin should be used only in 
limited circumstances because of concerns about resistance 
development to macrolides. The 1 g dose is not recommended 
because of documented treatment failures, and concerns 
about rapid emergence of antimicrobial resistance are even 
greater than with the 2 g dose.45,59,60
All alternative regimens for gonorrhea are considered 
inferior to ceftriaxone, because of lower efficacy in urogeni-
tal and rectal infection and unacceptably low cure rates for 
oropharyngeal infection. Cure of gonococcal infection may 
become increasingly elusive, given growing clinical and in 
vitro resistance patterns.61
Gonococcal infections of the pharynx are more difficult 
to eradicate than infections at urogenital and anorectal 
sites, leaving ceftriaxione 250 mg intramuscularly as the 
single drug of choice.62 Two treatment failures have been 
reported and sensitivity of gonococcal isolates to ceftriax-
one has been steadily declining.53,61 This trend is expected 
to continue.
Women diagnosed with gonococcal conjunctivitis should 
undergo saline lavage of the infected eye and be treated with 
high-dose ceftriaxone.63
Complicated gonococcal infections
Disseminated gonococcal infection is a serious infection, 
for which hospitalization is recommended in consultation 
with an infectious disease specialist, both for initiation of 
treatment as well as for completion of a diagnostic evalu-
ation for endocarditis and meningitis. Parenteral therapy 
should be continued for 24–48 hours after improvement 
begins, at which time therapy can be switched to oral 
therapy to complete at least 1 week of antimicrobial therapy 
(Table 1). Prolonged duration of therapy is required for 
other complicated infections as well, including 10–14 days 
for meningitis, and at least 4 weeks for endocarditis 
(Table 1).
Pelvic inflammatory disease
Given the asymptomatic nature of lower genital tract gono-
coccal infection, nearly one in five women who do not International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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receive treatment will develop pelvic inflammatory disease.64 
Women diagnosed with pelvic inflammatory disease may 
have lower and or upper genital tract evidence of a number 
of microbes, including N. gonorrhoeae and C. trachomatis, 
and a large number of Gram-negative and anaerobic bacteria. 
Negative lower tract screening for certain bacteria does not 
rule out upper reproductive tract infection, and treatment 
  recommendations favor coverage against these various 
organisms (Table 2). Treatment may be administered in 
inpatient or outpatient settings, and there are regimens that 
are   primarily parenteral and others that are primarily oral, 
choices which should be undertaken based on the severity 
of the infection.35
Cotreatment for C. trachomatis
Because women with gonorrhea are frequently coinfected 
with chlamydia, treatment for gonococcal infection at all sites 
and of all levels of severity should include antibiotics that 
eradicate both N. gonorrhoeae and C. trachomatis.65 Because 
most gonococci in the US are susceptible to doxycycline 
and azithromycin, routine cotreatment might also hinder 
the development of antimicrobial-resistant N. gonorrhoeae. 
Limited data suggest that dual treatment with azithromycin 
might enhance treatment efficacy for pharyngeal infection 
when using oral cephalosporins.66
Special populations
Pregnant women and women who are HIV-infected and 
diagnosed with gonorrhea should be treated according to 
standard recommendations.
Allergic reactions
Up to 10% of individuals with a history of penicillin 
allergy develop an adverse reaction to first-generation 
cephalosporins, and fewer react to third-generation cepha-
losporins.67 Cephalosporin use should be avoided only 
Table 1 Treatment recommendations for gonococcal infections in women1
Site Antimicrobial regimen
Component 1 Component 2
Lower genital  
tract and  
ano-rectum
Recommended Ceftriaxone 250 mg IM in a single dose
OR, IF NOT AN OPTION
Cefixime 400 mg orally in a single dose
OR Azithromycin 1 g orally in a single dose
Ceftizoxime 500 mg IM in a single dose PLUS OR
OR
Cefoxitin 2 g IM + Probenecid 1 g  
orally, in single doses
Doxycycline 100 mg orally twice a 
day for 7 days
OR
Cefotaxime 500 mg IM in a single dose
Alternative Cefpodoxime 400 mg orally in a single dose PLUS Azithromycin 2 g orally in a single dose
OR
Cefpodoxime proxetil 200 mg  
orally in a single dose
OR
Cefuroxime axetil 1 g orally in a single dose
Pharynx Recommended Ceftriaxone 250 mg IM in a single dose Azithromycin 1 g orally in a single dose
PLUS OR
Doxycycline 100 mg orally twice a  
day for 7 days
Conjunctivae Recommended Ceftriaxone 1 g IM in a single dose
Disseminated  
gonococcal  
infection (DIC)
Recommended Ceftriaxone 1 g IM or Iv every 24 hours2
Cefotaxime 1 g Iv every 8 hours2 PLUS Cefixime 400 mg orally twice a day
Alternative OR to complete a 7 day course
Ceftizoxime 1 g Iv every 8 hours2
Meningitis Recommended Ceftriaxone 1–2 g Iv every  
12 hours for 10–14 days
endocarditis Recommended Ceftriaxone 1–2 g Iv every  
12 hours for at least 4 weeks
Notes:  1Adapted from the 2010 CDC STD treatment guidelines;35  2Parenteral treatment should be continued until 24 hours following the improvement of clinical 
symptoms.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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in those with a history of a severe reaction to penicillin 
(eg, anaphylaxis, Stevens Johnson syndrome, and toxic 
epidermal necrolysis),68 and further treatment decisions 
should be made in consultation with an infectious disease 
specialist.
Follow-up
Women treated with any of the recommended or alternative 
regimens for an uncomplicated episode of N. gonorrhoeae do 
not need a test-of-cure 3–4 weeks after completing therapy, 
but should be retested 3 months after treatment or the next 
time they seek medical care irrespective of partner treatment.69 
Because reinfection within a few months is common,70–72 
patient education regarding safer sexual practices and partner 
referral is warranted. If symptoms persist following treatment, 
women should be tested for other pathogens and re-evaluated 
by culture for N. gonorrhoeae; any gonococci isolated should 
be tested for antimicrobial susceptibility.
Sex partners of patients with N. gonorrhoeae   infection 
whose last sexual contact with the patient was within 
Table 2 Treatment recommendations for pelvic inflammatory disease1
Route of  
administration
Antimicrobial regimen
Parenteral component2 Oral component
Parenteral + oral Regimen A Cefotetan 2 g Iv every 12 hours Doxycycline 100 mg orally twice a 
day  
to complete a 14-day course
PLUS, when tubo-ovarian abscess is  
present,
OR PLUS
Cefoxitin 2 g Iv every 6 hours
PLUS
Doxycycline 100 mg orally or  
Iv every 12 hours
Regimen B Clindamycin 900 mg Iv every 8 hours PLUS Clindamycin 450 mg orally four times  
a day to complete a 14-day course
OR
PLUS
Gentamicin loading dose 2 mg/kg Iv or IM,  
followed by a maintenance dose of 1.5 mg/kg  
every 8 hours. Single daily dosing (3–5 mg/kg)  
can be substituted
Alternative Ampicillin/Sulbactam 3 g Iv every 6 hours
PLUS PLUS Metronidazole 500 mg orally  
two times a day tocomplete a  
14-day course
Doxycycline 100 mg orally or Iv every  
12 hours
Oral Recommended Ceftriaxone 250 mg IM in a  
single dose
OR
Cefoxitin 2 g IM in a single dose  
and Probenecid, 1 g orally  
administered concurrently in a 
single dose
OR
Other parenteral third-generation 
cephalosporin  
(eg, ceftizoxime or cefotaxime)
PLUS
Doxycycline 100 mg orally twice  
a day for 14 days
WITH or WITHOUT
Metronidazole 500 mg orally twice  
a day for 14 days
Alternative Ceftriaxone 250 mg IM in a  
single dose
PLUS
Azithromycin 1 g orally once  
a week for two weeks
WITH or WITHOUT
Metronidazole 500 mg orally  
twice a day for 14 days
Notes: 1Adapted from the 2010 CDC STD treatment guidelines;35  2Parenteral treatment should be continued until 24 hours following the improvement of clinical 
symptoms.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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60 days of the onset of symptoms or diagnosis of   infection 
in the patient should be evaluated and treated for 
N.   gonorrhoeae and C. trachomatis. If a patient’s last 
sexual intercourse was .60 days before onset of symptoms 
or diagnosis, the patient’s most recent sex partner should 
be treated. For those whose partners’ treatment cannot be 
ensured or is unlikely, delivery of antibiotic therapy for 
gonorrhea (as well as for chlamydia) by the patients to their 
partners should be considered, accompanied by efforts to 
educate partners about symptoms and to encourage partners 
to seek clinical evaluation.73,74
Suspected treatment failure is less common than 
reinfection, but has been reported, especially among per-
sons receiving regimens other than the 250 mg dose of 
ceftriaxone.49,53,56–58 Clinicians of patients with suspected 
treatment failure or persons found to harbor a resistant 
strain should consult an infectious disease specialist, con-
duct   culture and susceptibility testing of relevant clinical 
specimens, re-treat with at least 250 mg of ceftriaxone 
intramuscularly or intravenously, ensure partner treatment, 
and report the situation to the CDC through state and local 
public health authorities.35
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